Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 252

1.

Combination Therapy Improves Vascular Volume in Female Rats with Pulmonary Hypertension.

Lachant D, Meoli DF, Haight D, Staicu S, Akers S, Glickman S, Ambrosini R, Champion HC, White RJ.

Am J Physiol Lung Cell Mol Physiol. 2019 Jul 19. doi: 10.1152/ajplung.00450.2018. [Epub ahead of print]

PMID:
31322432
2.

Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.

Todorović V, Su Z, Putman CB, Kakavas SJ, Salte KM, McDonald HA, Wetter JB, Paulsboe SE, Sun Q, Gerstein CE, Medina L, Sielaff B, Sadhukhan R, Stockmann H, Richardson PL, Qiu W, Argiriadi MA, Henry RF, Herold JM, Shotwell JB, McGaraughty SP, Honore P, Gopalakrishnan SM, Sun CC, Scott VE.

Sci Rep. 2019 Jun 24;9(1):9089. doi: 10.1038/s41598-019-45626-w.

3.

What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.

Li Q, Kuang HY, Wu YH, Lu TW, Yi QJ.

Medicine (Baltimore). 2019 May;98(20):e15632. doi: 10.1097/MD.0000000000015632.

4.

Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry.

Chazova IE, Arkhipova OA, Martynyuk TV.

Ter Arkh. 2019 Mar 10;91(1):24-31. doi: 10.26442/00403660.2019.01.000024.

PMID:
31090367
5.

Role of ambrisentan (selective endothelin-A receptor antagonist) on cigarette smoke exposure induced cognitive impairment in Danio rerio.

Muthuraman A, Nafisa K, Sowmya MS, Arpitha BM, Choedon N, Sandy CD, Rishitha N, Johurul I.

Life Sci. 2019 Apr 1;222:133-139. doi: 10.1016/j.lfs.2019.03.002. Epub 2019 Mar 4.

PMID:
30844374
6.

Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases.

Ferguson SK, Pak DI, Hopkins JL, Harral JW, Redinius KM, Loomis Z, Stenmark KR, Borden MA, Schroeder T, Irwin DC.

Drug Deliv. 2019 Dec;26(1):147-157. doi: 10.1080/10717544.2019.1568621.

7.

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review.

You R, Qian X, Tang W, Xie T, Zeng F, Chen J, Zhang Y, Liu J.

Can Respir J. 2018 Nov 18;2018:1015239. doi: 10.1155/2018/1015239. eCollection 2018.

8.

A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension.

Wang S, Yu M, Zheng X, Dong S.

Drug Deliv. 2018 Nov;25(1):1898-1909. doi: 10.1080/10717544.2018.1523257.

9.

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?

Correale M, Ferraretti A, Monaco I, Grazioli D, Di Biase M, Brunetti ND.

Vasc Health Risk Manag. 2018 Oct 4;14:253-264. doi: 10.2147/VHRM.S133921. eCollection 2018. Review.

10.

Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations.

Lombardi S, Kingman M, Duncan M, Berngard SC, Fernandes T.

Respir Med. 2018 Oct;143:139-146. doi: 10.1016/j.rmed.2018.09.002. Epub 2018 Sep 5. Review.

PMID:
30261985
11.

Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine.

Ribeiro Baptista B, Petitpain N, Gomez E, Yelehé-Okouma M, Valentin S, Guillaumot A, Chabot F, Chaouat A.

Fundam Clin Pharmacol. 2019 Feb;33(1):127-129. doi: 10.1111/fcp.12396. Epub 2018 Jul 15.

PMID:
29956855
12.

New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine.

Davenport AP, Kuc RE, Southan C, Maguire JJ.

Physiol Res. 2018 Jun 27;67(Supplementum 1):S37-S54. Review.

13.

Current and Future Treatments for Persistent Pulmonary Hypertension in the Newborn.

Pedersen J, Hedegaard ER, Simonsen U, Krüger M, Infanger M, Grimm D.

Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):392-406. doi: 10.1111/bcpt.13051. Epub 2018 Jul 19. Review.

PMID:
29855164
14.

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study.

Gong SG, Wang L, Pudasaini B, Yuan P, Jiang R, Zhao QH, He J, Zhang R, Wu WH, Liu JM, Zhou CC.

Can Respir J. 2018 Apr 11;2018:9836820. doi: 10.1155/2018/9836820. eCollection 2018.

15.

Can results from a Japanese pulmonary hypertension registry have an impact on Western guidelines?

Tanabe N.

Respir Investig. 2018 Jul;56(4):263-264. doi: 10.1016/j.resinv.2018.02.004. Epub 2018 Mar 13. No abstract available.

PMID:
29764745
16.

A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.

Bedan M, Grimm D, Wehland M, Simonsen U, Infanger M, Krüger M.

Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):103-113. doi: 10.1111/bcpt.13033. Epub 2018 Jun 5. Review.

17.

Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study.

Dawson A, Reddecliffe S, Coghlan C, Schreiber BE, Coghlan JG.

Eur J Cardiovasc Nurs. 2018 Oct;17(7):612-618. doi: 10.1177/1474515118769534. Epub 2018 Apr 11.

PMID:
29641223
18.

Amelioration of right ventricular systolic function and stiffness in a patient with idiopathic pulmonary arterial hypertension treated with oral triple combination therapy.

Nakaya T, Tsujino I, Ohira H, Sato T, Watanabe T, Oyama-Manabe N, Nishimura M.

Pulm Circ. 2018 Apr-Jun;8(2):2045894018765350. doi: 10.1177/2045894018765350. Epub 2018 Feb 28.

19.

Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.

Burger CD, Ozbay AB, Lazarus HM, Riehle E, Montejano LB, Lenhart G, White RJ.

J Manag Care Spec Pharm. 2018 Aug;24(8):834-842. doi: 10.18553/jmcp.2018.17391. Epub 2018 Feb 13.

20.

Enhancement of solubility and bioavailability of ambrisentan by solid dispersion using Daucus carota as a drug carrier: formulation, characterization, in vitro, and in vivo study.

Deshmane S, Deshmane S, Shelke S, Biyani K.

Drug Dev Ind Pharm. 2018 Jun;44(6):1001-1011. doi: 10.1080/03639045.2018.1428339. Epub 2018 Feb 5.

PMID:
29382236

Supplemental Content

Loading ...
Support Center